After two consecutive years of 20%-plus gains, the S&P 500 kicked off 2025 with a solid January performance. Investors are hoping the S&P 500 can continue to grind higher and maintain its ...

Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Q4 2024 Earnings Call Transcript January 28, 2025 Stryker Corporation beats earnings expectations. Reported EPS is $4.01, ...

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Inc. (NARI) has reached a new 52-week high, with its stock price climbing to $79.7, marking a significant milestone for the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Inari Medical Inc., one of Orange County’s fastest-growing medical device makers, is being acquired for $4.9 billion by global medical technology company Stryker Corp. Stryker on Jan. 6 announced an ...

In this article, we are going to take a look at where Inari Medical Inc. (NASDAQ:NARI) stands against the other stocks. Ten companies finished stronger this week, outpacing the broader market ...

Irvine-based Inari Medical Inc. will be acquired by Stryker Corp. for $4.8 billion. The boards of directors of both companies have approved the transaction, and it’s expected to close in the ...

Acquisition expected to strengthen Stryker’s neurovascular business with Inari VTE product portfolio including mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal dilution. Inari shareholders are getting a fair price relative to the ...